Podcasts about orexigen

In Re Orexigen Therapeutics

In Re Orexigen Therapeutics

Winning regulatory approval for a drug to treat obesity would seem like a great accomplishment, but for Orexigen Therapeutics, that's when the hard work began. After its marketing partner Takeda ended their agreement because of disappointing sales, the company found itself in the position of having to market a drug to doctors who often don't consider obesity an illness and believe willpower and discipline, not a pill, is what's needed. Orexigen's solution centered on a novel approach. The company decided to make a pitch directly to patients and connect them to telehealth-based doctors, who could ensure use of the drug is appropriate and help them avoid the embarrassment they may feel when speaking to their own doctors. We spoke to Thomas Cannell, Chief Operating Officer and President of Global Commercial Products for Orexigen, about its obesity drug Contrave, its marketing strategy, and whether it represents a marketing model that others may follow.

Salma Jutt, Vice President of Marketing US, Orexigen Theraputics talks about their obesity drug CONTRAVE and how it works on two areas of the brain to reduce hunger and cravings.  This is a drug for those committed to stick to a regime of exercise and diet and can help keep the weight off.  A growing business in this age of selfies where there is an increasing interest in improving appearances and nearly unlimited opportunities to satisfy cravings for the wrong foods. CONTRAVE.com

Today in FirstWord:

Today in FirstWord:

MannKind and Orexigen: two companies with big promise, but can they deliver on profit? Healthcare analyst Michael Douglass and healthcare contributor Todd Campbell discuss the risks facing these biotech stocks.

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

It’s August 2009 and in the last 12 months, Lou Bock‘s portfolio has had some impressive success. He talks about how Zogenix, Horizon Therapeutics, Somaxon, Prestwick Pharmaceuticals and Orexigen have all done well. The Scale Venture Partners Managing Director has seen two positive Phase III outcomes, 2 FDA approvals and one progressing to approval since […]